Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
NEW YORK, Dec. 07, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Arrowhead Pharmaceuticals, Inc. (“Arrowhead”) (NASDAQ:ARWR) between May 11, 2015 and November 29, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. To get more information go to:
http://www.zlk.com/pslra/arrowhead-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Arrowhead made false and misleading statements and/or failed to disclose that: (1) its drug candidate ARC-520 was fatal at certain doses; (2) the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; (3) the Company overstated the approval prospects and commercial viability of ARC-520; and (4) as a result of the above, Arrowhead’s public statements were materially false and misleading at all relevant times.
On November 8, 2016, after the close of the market, Arrowhead Pharmaceuticals announced that the United States Food & Drug Administration had decided to place a clinical hold on the Company’s Heparc-2004 clinical study of ARC-520. Then on November 29, 2016, Arrowhead announced it would discontinue the development of 3 hepatitis treatments and trim its workforce by 30 percent.
If you suffered a loss in Arrowhead you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
